Humacyte Director Paul Brian Kuznik Receives 125,000 Stock Options with $0.478 Exercise Price
Alpha Vantage · Kalkine Media · · AI-summarised by FinFlash
Humacyte, Inc. Director Paul Brian Kuznik was granted 125,000 stock options with an exercise price of $0.478 per share, as reported in a recent SEC Form 4 filing. These options, dated October 6, 2026, will fully vest by October 6, 2030, following a scheduled vesting plan and will expire on October 6, 2036. The transaction highlights the acquisition of derivative securities by an insider.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.